Nanobiotix S.A. (NASDAQ:NBTX) Q1 2022 Earnings Conference Call May 19, 2022 8:00 AM ET
Company Participants
Kate McNeil – Senior Vice President, Investor Relations
Laurent Levy – Co-Founder and Chief Executive Officer
Bart Van Rhijn – Chief Financial Officer
Conference Call Participants
Lucy Codrington – Jefferies
Michael DiFiore – Evercore
Clément Bassat – Portzamparc
RK Swayampakula – H.C. Wainwright
Frédéric Gomez – Pharmium Securities
Operator
Good day, and thank you for standing by. Welcome to the Nanobiotix First Quarter Operational and Financial Update. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today’s conference is being recorded, Thursday, May 19, 2022. [Operator Instructions]
I would now like to hand the conference over to your speaker today, Kate McNeil. Please go ahead.
Kate McNeil
Thank you, operator. Good afternoon, and good morning, and welcome to Nanobiotix conference call to discuss our first quarter 2022 financial and operational results. Joining me on the call today are Laurent Levy, Co-Founder and Chief Executive Officer; and Bart Van Rhijn, Chief Financial Officer.
As a reminder, today’s call is being webcast and will be available on our website for replay. I’d like to remind you that this call will include forward-looking statements, which may include statements regarding the progress, success, and timing of our ongoing and planned clinical trials, collaboration, regulatory filings, dates of presentation, and future research and development efforts, among other things.
These forward-looking statements are based on current information, assumptions, and expectation that are subject to change. They are subject to significant risks and uncertainties that could cause the company’s actual results to differ materially from our current expectations. Accordingly, you are cautioned not to place undue reliance on forward-looking statements. Please review the full description of risk factor that can be found in the documents we filed with the AMF in France, and SEC in the United States, including our most recent URD and 20-F both of which are available in the Investor Relations section of our website, along with the press release issued yesterday highlighting our corporate and financial results for the period.
In addition, any forward-looking statements represent our views only as of today and should not be relied upon as representing our views as of any subsequent date. While we may elect to update these forward-looking statements at some point in the future, Nanobiotix undertakes no obligation to update them to reflect subsequent events or future circumstances.